Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;51(3):1073-1085.
doi: 10.4143/crt.2018.357. Epub 2018 Nov 1.

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer

Sae Byul Lee  1 , Junetae Kim  2 , Guiyun Sohn  1 , Jisun Kim  1 , Il Yong Chung  1 , Hee Jeong Kim  1 , Beom Seok Ko  1 , Byung Ho Son  1 , Sei-Hyun Ahn  1 , Jong Won Lee  1 , Kyung Hae Jung  3
Affiliations

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer

Sae Byul Lee et al. Cancer Res Treat. 2019 Jul.

Abstract

Purpose: This preliminary study was conducted to evaluate the association between Oncotype DX (ODX) recurrence score and traditional prognostic factors. We also developed a nomogram to predict subgroups with low ODX recurrence scores (less than 25) and to avoid additional chemotherapy treatments for those patients.

Materials and methods: Clinicopathological and immunohistochemical variables were retrospectively retrieved and analyzed from a series of 485 T1-3N0-1miM0 hormone receptor-positive, human epidermal growth factor 2‒negative breast cancer patients with available ODX test results at Asan Medical Center from 2010 to 2016. One hundred twenty-seven patients (26%) had positive axillary lymph node micrometastases, and 408 (84%) had ODX recurrence scores of ≤25. Logistic regression was performed to build a nomogram for predicting a low-risk subgroup of the ODX assay.

Results: Multivariate analysis revealed that estrogen receptor (ER) score, progesterone receptor (PR) score, histologic grade, lymphovascular invasion (LVI), and Ki-67 had a statistically significant association with the low-risk subgroup. With these variables, we developed a nomogram to predict the low-risk subgroup with ODX recurrence scores of ≤25. The area under the receiver operating characteristic curve was 0.90 (95% confidence interval [CI], 0.85 to 0.96). When applied to the validation group the nomogram was accurate with an area under the curve = 0.88 (95% CI, 0.83 to 0.95).

Conclusion: The low ODX recurrence score subgroup can be predicted by a nomogram incorporating five traditional prognostic factors: ER, PR, histologic grade, LVI, and Ki-67. Our nomogram, which predicts a low-risk ODX recurrence score, will be a useful tool to help select patients who may or may not need additional ODX testing.

Keywords: Breast neoplasms; Nomogram; Oncotype; Prediction; Prognosis; Recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1.
Fig. 1.
Nomogram to predict low-risk recurrence score of Oncotype Dx. LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor.
Fig. 2.
Fig. 2.
Receiver operating characteristic curve (ROC) of nomogram. (A) Training dataset of 340 patients. (B) Validation dataset of 145 patients.
Fig. 3.
Fig. 3.
Kaplan-Meier analysis of external validation group according to cutoff of 97. (A) Disease-free survival. (B) Distant metastasis-free survival. (C) Overall survival.
Fig. 4.
Fig. 4.
Nomogram model. (A) Online application. (B) Mobile application. (C) Automatic calculator using Microsoft Excel worksheets.
See this image and copyright information in PMC

References

    1. Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat. 2005;89:47–54. - PubMed
    1. Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer. 1984;49:709–15. - PMC - PubMed
    1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551–7. - PubMed
    1. Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat. 2009;115:241–54. - PubMed
    1. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 2002;41:154–61. - PubMed

MeSH terms